Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX’s Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner
Entirely Reconstituted Board and New Management Team Positioned Company for Long-Term Sustainable Growth; Stock Price Appreciation of 237% Since Timothy Wright Selected as CEO
Virtual Annual Meeting to Be Held on May 27, 2021
MARIETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders (“Annual Meeting”), to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21 vm. MIMEDX shareholders of record at as of 5:00 p.m. Eastern Time on April 16, 20
MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
April 28, 2021 10:21 ET | Source: MiMedx Group, Inc MiMedx Group, Inc
Accomplished Regulatory Leader Joins MiMedx Management Team
MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the addition of Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs, effective May 3, 2021. Dr. Stevens, who brings more than 35 years of strategic leadership experience in quality management and regulatory compliance across multiple medical device and pharmaceutical companies, joins MiMedx from Smith & Nephew, plc, where he was accountable for regulatory submissions, compliance, and Commercial Quality Assurance.